Feinsod Matthew 4
4 · Kalaris Therapeutics, Inc. · Filed Apr 11, 2025
Insider Transaction Report
Form 4
Feinsod Matthew
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2025-04-10+101,000→ 101,000 totalExercise: $7.31Exp: 2035-04-09→ Common Stock (101,000 underlying) - Award
Stock Option (Right to Buy)
2025-04-10+70,551→ 70,551 totalExercise: $7.31Exp: 2035-04-09→ Common Stock (70,551 underlying)
Footnotes (2)
- [F1]The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on December 31, 2025, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.
- [F2]The option was granted on April 10, 2025. The shares underlying the option are scheduled to vest over four years, with 25% of the shares underlying the option vesting on March 18, 2026, and the remainder vesting in equal monthly installments thereafter, subject to continuous service.